MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Alcon Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

94.57 0.86

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

93.67

Max

94.99

Pagrindiniai rodikliai

By Trading Economics

Pajamos

21M

284M

Pardavimai

48M

2.5B

P/E

Sektoriaus vid.

44.576

57.333

Pelnas, tenkantis vienai akcijai

0.72

Dividendų pajamingumas

0.36

Pelno marža

11.351

Darbuotojai

25,599

EBITDA

56M

397M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+16.81% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.36%

2.63%

Kitas uždarbis

2025-05-13

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

4.4B

46B

Ankstesnė atidarymo kaina

93.71

Ankstesnė uždarymo kaina

94.57

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bullish Evidence

Alcon Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-03-26 21:22; UTC

Įsigijimai, susijungimai, perėmimai

Alcon Buys Majority Stake in Aurion to Advance Eye Disease Treatment

2025-03-24 12:36; UTC

Įsigijimai, susijungimai, perėmimai

Alcon to Buy Lensar in Deal Worth Up to $430 Million

2024-11-12 18:48; UTC

Uždarbis
Pagrindinės rinkos jėgos

Alcon Posts Higher 3Q Sales and Profit, Lowers 2024 Sales View

2025-04-08 08:20; UTC

Rinkos pokalbiai

Med-Tech Investors Seek 'Safe Havens' Amid Tariff Fears -- Market Talk

2025-03-26 21:55; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Alcon Deal for Aurion Follows 2022 Investment, 2024 Lawsuit -- Market Talk

2025-03-26 20:33; UTC

Įsigijimai, susijungimai, perėmimai

Aurion Board Appoints Arnaud Lacoste as CEO of Aurion

2025-03-26 20:32; UTC

Įsigijimai, susijungimai, perėmimai

Alcon: Aurion Will Operate as a Separate Company With Full Support From Alcon to Advance Its Clinical-Stage Allogeneic Cell Therapy Asset

2025-03-26 20:32; UTC

Įsigijimai, susijungimai, perėmimai

Leverages Alcon's Global Scale With Aurion's Cell Therapy Expertise to Accelerate U.S. Phase 3 Development in Fall of 2025 >ALC.EB

2025-03-26 20:31; UTC

Įsigijimai, susijungimai, perėmimai

Alcon Acquires Interest in Aurion to Advance Innovative Cell Therapy for Corneal Endothelial Disease >ALC.EB

2025-03-26 20:31; UTC

Įsigijimai, susijungimai, perėmimai

Alcon Inc. Unit Alcon Research Previously Sued Aurion to Prevent It From Going Public

2025-03-26 20:31; UTC

Įsigijimai, susijungimai, perėmimai

Alcon Acquires Majority Interest in Aurion Biotech >ALC.EB

2025-03-26 20:30; UTC

Įsigijimai, susijungimai, perėmimai

Alcon Acquires Majority Interest in Aurion Biotech

2025-03-24 12:21; UTC

Įsigijimai, susijungimai, perėmimai

Alcon to Buy Lensar in Deal Worth Up to $430M

2025-03-24 12:05; UTC

Įsigijimai, susijungimai, perėmimai

Alcon: Transaction Is Anticipated to Close in Mid-To-Late 2025 >ALC

2025-03-24 12:05; UTC

Įsigijimai, susijungimai, perėmimai

Alcon: Transaction Represents a Total Consideration of Up to About $430M >ALC

2025-03-24 12:04; UTC

Įsigijimai, susijungimai, perėmimai

Alcon: Additional Non-Tradeable Contingent Value Right Offering Up to $2.75 Per Shr in Cash, Conditioned on Achievement of 614,000 Cumulative Procedures With LENSAR's Products Between Jan 1, 2026, and Dec 31, 2027 >ALC

2025-03-24 12:04; UTC

Įsigijimai, susijungimai, perėmimai

Alcon Will Purchase All Outstanding Shrs of LENSAR for $14.00 Per Shr in Cash >ALC

2025-03-24 12:03; UTC

Įsigijimai, susijungimai, perėmimai

Alcon: Acquisition Includes ALLY Robotic Cataract Laser Treatment System, LENSAR's Proprietary Streamline Software Technology and LENSAR Legacy Laser System >ALC

2025-03-24 12:03; UTC

Įsigijimai, susijungimai, perėmimai

Alcon Agrees to Acquire LENSAR >ALC

2025-03-24 12:00; UTC

Įsigijimai, susijungimai, perėmimai

Alcon Agrees To Acquire LENSAR, Inc. >ALC LNSR

2025-02-25 21:33; UTC

Uždarbis

Alcon Sees 2025 Adj EPS $3.15-Adj EPS $3.25 >ALC.EB

2025-02-25 21:33; UTC

Uždarbis

Alcon Sees 2025 Sales $10.2B-$10.4B >ALC.EB

2025-02-25 21:32; UTC

Uždarbis

Alcon: Board Authorized the Repurchase of Up to $750M of the Company's Common Shrs >ALC.EB

2025-02-25 21:31; UTC

Uždarbis

Alcon 4Q EPS 57c >ALC.EB

2025-02-25 21:31; UTC

Uždarbis

Alcon 4Q Rev $2.5B >ALC.EB

2024-12-17 15:05; UTC

Rinkos pokalbiai

Alcon's Late-Stage Pipeline Set To Drive Revenue Growth Next Year -- Market Talk

2024-11-12 17:38; UTC

Uždarbis

Alcon Narrows 2024 View To Adj EPS $3.00-Adj EPS $3.05 >ALC

2024-11-12 17:38; UTC

Uždarbis

Alcon Had Seen 2024 Sales $9.9B-$10.1B >ALC

2024-11-12 17:37; UTC

Uždarbis

Alcon Cuts 2024 View To Sales $9.8B-$9.9B >ALC

2024-11-12 17:36; UTC

Uždarbis

Alcon 3Q Core Operating Margin 20.6% >ALC

Akcijų palyginimas

Kainos pokytis

Alcon Inc Prognozė

Kainos tikslas

By TipRanks

16.81% į viršų

12 mėnesių prognozė

Vidutinis 110.6 USD  16.81%

Aukščiausias 120.43 USD

Žemiausias 90 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Alcon Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

17

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

91.47 / 95.33Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Alcon Inc

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.